Product Information
ROFLUMILAST 250 MCG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $1.9969 per EA under NDC 68382062431. Its NADAC has been published 124 times since Apr 10, 2024.
FDA first approved this application on Feb 10, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 ug/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382062431
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ROFLUMILASTApproval Type
Generic (ANDA)
FDA Application
ANDA208303FDA Approved
2/10/2022
TE Code
AB
On Market Since
5/18/2023
Pharmacological Classes
Price Statistics
The NADAC for ROFLUMILAST 250 MCG TABLET has been published 124 times since Apr 10, 2024, and over the history we have for it it has declined 33.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9969 per EA |
|---|---|
| All-time high | $3.0148 (Apr 10, 2024) |
| All-time low | $1.5913 (Jul 17, 2024) |
| 52-week high | $2.4855 |
| 52-week low | $1.9069 |
| Median price | $2.3328 |
| Average price | $2.2946 |
| Largest weekly change | +63.4% (Aug 21, 2024) |
| Weeks tracked | 124 |
| Tracking since | Apr 10, 2024 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ROFLUMILAST 250 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $1.9969 per EA (NDC 68382062431), effective Aug 19, 2026.
How has the price of ROFLUMILAST 250 MCG TABLET changed over time?
Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 33.8%. It has been tracked across 124 weekly CMS publications since Apr 10, 2024.
What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?
Since Apr 10, 2024, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.5913 (Jul 17, 2024) to a high of $3.0148 (Apr 10, 2024), with a median of $2.3328 per EA.
Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROFLUMILAST 250 MCG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ROFLUMILAST 250 MCG TABLET?
ROFLUMILAST 250 MCG TABLET (NDC 68382062431) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.